News

IFN-beta is an established treatment for multiple sclerosis; however its short life in human serum necessitates frequent injections for the patient, and has associated side effects. The next

The company recently came to an agreement with Swiss company Stragen Pharma in order to accelerate the development of Ceflatonin, and these trials will take advantage of Strangen’s

John Castello, chairman, president and CEO of Xoma commented, “Although Zephyr has devoted both time and effort toward the advancement of BPI, they have not met the financing

A maximum of 24 eligible patients will be entered into this dose-seeking study, which will test the safety of increasing doses of Rexin-G, given intravenously, in patients with

Researchers found that PGE2, which is produced normally by epithelial cells but at very high levels in lung cancer and other malignancies, up-regulates the activity of lymphocytes called

Chiron has now reduced its supply expectations for Begrivac for the 2005-2006 influenza season by approximately eight million doses and may delay shipments until early October. The biotech

The NIH investment will help establish the Center for HIV/AIDS Vaccine Immunology (CHAVI), which will be led by Dr Barton Haynes, director of Duke University’s Human Vaccine Institute.

According to the company, this new formulation will be in pharmacies across the US in September 2005, and will be available in both a 2.5mg and a 5mg

Although US regulators deemed Chiron’s application to be “approvable”, an additional pre-approval study was said to be required to confirm the efficacy of the drug. Chiron is seeking